Elan Investment In Zonegran Marketing Instead Of Clinical Trails Proves Costly In DoJ Settlement
This article was originally published in The Pink Sheet Daily
Elan agrees to pay $203.5 million in criminal and civil fines and to enter a corporate integrity agreement; DoJ's complaint cites sales techniques the company developed to encourage doctors to prescribe off-label.
You may also be interested in...
Abbott Laboratories is the third pharmaceutical company to reach a settlement with the Department of Justice in excess of $1 billion. A look at the deals struck since Eli Lilly began the billion dollar club in 2009 shows the activities the government is investigating and the level of liability that companies face.
The company agrees to pay $422.5 million to resolve civil and criminal claims related to off-label use and kickbacks, including allegations that it paid doctors' speaking and consulting fees based upon the volume of prescriptions they wrote for its hypertension drugs.